EGEdward Griffen

Edward Griffen

*This is an algorithmically generated author record based on publicly available information.

Edward Griffen has a total of 310 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Top Cited Papers

    A Computational Community Blind Challenge on Pan-Coronavirus Drug Discovery Data

    by Hugo MacDermott-Opeskin, Jenke Scheen, Cas Wognum, Joshua T. Horton, Devany West, Alexander Matthew Payne, Maria A. Castellanos, Sean Colby, Edward Griffen, David Cousins, et al.

    Computational blind challenges offer critical, unbiased opportunities to assess and accelerate scientific progress, as demonstrated by a breadth of breakthroughs over the past decade. We report the outcomes and key insights from an open science community blind challenge focused on computational methods in drug discovery, using lead optimization data from the AI-driven Structure-enabled Antiviral Platform Discovery Consortium's pan-coronavirus antiviral discovery program, in partnership with Polaris and the OpenADMET project. This collaborative initiative invited global participants from both academia and industry to develop and apply computational methods to predict the biochemical potency and crystallographic ligand poses of small molecules against key coronavirus targets, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) main protease (Mpro), as well as multiple ADMET assay end points, using previously undisclosed comprehensive experimental drug discovery data sets as benchmarks. By evaluating submissions across multiple tasks and compounds, we established performance leaderboards and conducted meta-analyses to assess methodological strengths, common pitfalls, and areas for improvement. This analysis provides a foundation for best practices in real-world machine learning evaluation, grounded in community-driven benchmarking. We also highlight how next-generation platforms, such as Polaris, enable rigorous challenge design, embedded evaluation frameworks, and broad community engagement. This paper reports the collective findings of the challenge, offering a high-level overview of the data, evaluation infrastructure, and top-performing strategies. We further provide context and support for the accompanying papers authored by the challenge participants in this special issue, which explore individual approaches in greater depth. Together, these contributions aim to advance reproducible, trustworthy, and high-impact computational methods in drug discovery, and to explore best practices and pitfalls in future blind challenge design and execution, including planned initiatives for the OpenADMET project.


  • Open Access

    A Computational Community Blind Challenge on Pan-Coronavirus Drug Discovery Data

    by Hugo MacDermott-Opeskin, Jenke Scheen, Cas Wognum, Joshua T. Horton, Devany West, Alexander Matthew Payne, Maria A. Castellanos, Sean Colby, Edward Griffen, David Cousins, et al.

    Computational blind challenges offer critical, unbiased assessment opportunities to assess and accelerate scientific progress, as demonstrated by a breadth of breakthroughs over the last decade. We report the outcomes and key insights from an open science community blind challenge focused on computational methods in drug discovery, using lead optimization data from the AI-driven Structure-enabled Antiviral Platform (ASAP) Discovery Consortium’s pan-coronavirus antiviral discovery program, in partnership with Polaris and the OpenADMET project. This collaborative initiative invited global participants from both academia and industry to develop and apply computational methods to predict the biochemical potency and crystallographic ligand poses of small molecules against key coronavirus targets, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) main protease (Mpro), as well as multiple ADMET assay endpoints, using previously undisclosed comprehensive experimental drug discovery datasets as benchmarks. By evaluating submissions across multiple tasks and compounds, we established performance leaderboards and conducted meta-analyses to assess methodological strengths, common pitfalls, and areas for improvement. This analysis provides a foundation for best practices in real-world machine learning evaluation, grounded in community-driven benchmarking. We also highlight how next-generation platforms, such as Polaris, enable rigorous challenge design, embedded evaluation frameworks, and broad community engagement. This paper reports the collective findings of the challenge, offering a high-level overview of the data, evaluation infrastructure, and top- performing strategies. We further provide context and support for the accompanying papers authored by the challenge participants in this special issue, which explore individual approaches in greater depth. Together, these contributions aim to advance reproducible, trustworthy, and high-impact computational methods in drug discovery, and to explore best practices and pitfalls in future blind challenge design and execution, including planned initiatives for the OpenADMET project.

  • Open Access

    Expedient Synthesis of 1-Oxo-1,2,3,4-tetrahydroisoquinoline-4-carboxylates

    by Vitaliy A. Bilenko, Viktor Huliak, Serhii Kinakh, Ryan A. Inwood, Thomas Stowe, Elvis J. M. Maduli, Brian Broadbelt, Rosemary H. Crampton, Ed J. Griffen, Tetiana Matviiuk, et al.

    As a part of the ongoing COVID Moonshot project, an expedient approach to 1-oxo-1,2,3,4-tetrahydroisoquinoline-4-carboxylates is described. The method is based on a one-pot tandem Michael amination – lactamization sequence starting from of 2-(3-alkoxymethoxy-3-oxoprop-1-en-2-yl)benzoic acids and primary amines. The scope of the N-nucleophiles included various aliphatic, and aromatic, and heteroaromatic primary amines; the reaction tolerates and was compatible with ether, ester, amide, alcohol, carbamate, and free alcoholazole, or azine moieties. The developed protocol; allowed for the preparation of target tetrahydroisoqunoline derivatives in 40–75% yield on up to 109 g scale. A mechanistic scheme involving a ring-chain tautomerism for the electrophilic component of the reaction is proposed. The method was used in the synthesis of DNDI-6510, SARS-CoV-2 main protease inhibitor that showed promising results obtained in preclinical studies.

  • Open Access

    Author Correction: BWC0977, a broad-spectrum antibacterial clinical candidate to treat multidrug resistant infections

    by Shahul Hameed P, Harish Kotakonda, Sreevalli Sharma, Radha Nandishaiah, Nainesh Katagihallimath, Ranga Rao, Claire Sadler, Ian Slater, Michael Morton, Abhijeeth Chandrasekaran, et al.


  • Open Access

    Author Correction: BWC0977, a broad-spectrum antibacterial clinical candidate to treat multidrug resistant infections

    by Shahul Hameed P, Harish Kotakonda, Sreevalli Sharma, Radha Nandishaiah, Nainesh Katagihallimath, Ranga Rao, Claire Sadler, Ian Slater, Michael Morton, Abhijeeth Chandrasekaran, et al.

  • Open Access

    BWC0977, a broad-spectrum antibacterial clinical candidate to treat multidrug resistant infections

    by Shahul Hameed P, Harish Kotakonda, Sreevalli Sharma, Radha Nandishaiah, Nainesh Katagihallimath, Ranga Rao, Claire Sadler, Ian Slater, Michael Morton, Abhijeeth Chandrasekaran, et al.

    The global crisis of antimicrobial resistance (AMR) necessitates the development of broad-spectrum antibacterial drugs effective against multi-drug resistant (MDR) pathogens. BWC0977, a Novel Bacterial Topoisomerase Inhibitor (NBTI) selectively inhibits bacterial DNA replication via inhibition of DNA gyrase and topoisomerase IV. BWC0977 exhibited a minimum inhibitory concentration (MIC90) of 0.03–2 µg/mL against a global panel of MDR Gram-negative bacteria including Enterobacterales and non-fermenters, Gram-positive bacteria, anaerobes and biothreat pathogens. BWC0977 retains activity against isolates resistant to fluoroquinolones (FQs), carbapenems and colistin and demonstrates efficacy against multiple pathogens in two rodent species with significantly higher drug levels in the epithelial lining fluid of infected lungs. In healthy volunteers, single-ascending doses of BWC0977 administered intravenously (https://clinicaltrials.gov/study/NCT05088421) was found to be safe, well tolerated (primary endpoint) and achieved dose-proportional exposures (secondary endpoint) consistent with modelled data from preclinical studies. Here, we show that BWC0977 has the potential to treat a range of critical-care infections including MDR bacterial pneumonias.


  • Open Access

    Enabling equitable and affordable access to novel therapeutics for pandemic preparedness and response via creative intellectual property agreements

    by Ed J. Griffen, Pascale Boulet, Asap Discovery Center, Covid Moonshot

    The COVID-19 pandemic demonstrated that the current purely market-driven approaches to drug discovery and development alone are insufficient to drive equitable access to new therapies either in preparation for, or in response to, pandemics. A new global framework driven by equity is under negotiation at the World Health Organization to support pandemic preparedness and response. Some believe that the global intellectual property (IP) system itself is part of the problem and propose a purely Open Science approach. In this article, we discuss how existing IP frameworks and contractual agreements may be used to create rights and obligations to generate a more effective global response in future, drawing on experience gained in the COVID Moonshot program, a purely Open Science collaboration, and the ASAP AViDD drug discovery consortium, which uses a hybrid, phased model of Open Science, patent filing and contractual agreements. We conclude that ‘straight to generic’ drug discovery is appropriate in some domains, and that targeted patent protection, coupled with open licensing, can offer a route to generating affordable and equitable access for therapy areas where market forces have failed. The Extended Data contains a copy of our model IP policy, which can be used as a template by other discovery efforts seeking to ensure their drug candidates can be developed for globally equitable and affordable access.


  • Small molecule Son of Sevenless 1 (SOS1) inhibitors: a review of the patent literature

    by Severin K. Thompson, Andreas Buckl, Alexander G. Dossetter, Ed Griffen, Adrian Gill

    Introduction Up to 30% of all human cancers are driven by the overactivation of RAS signaling. Son of Sevenless 1 (SOS1) is a central node in RAS signaling pathways and modulation of SOS1-mediated RAS activation represents a unique opportunity for treating RAS-addicted cancers. Several recent publications and patent applications have demonstrated the ability of small molecules to affect the activation of RAS by SOS1 and have shown their potential for the treatment of cancers driven by RAS mutants. Areas covered Patent documents focusing on both small molecule inhibitors and activators of the SOS1:RAS interaction and their potential use as cancer therapeutics are covered. A total of 10 documents from 4 applicants are evaluated with discussion focusing on structural modifications of these small molecule inhibitors as well as relevant preclinical data. Expert opinion The last decade has seen a significant increase in research and disclosures in the development of small molecule SOS1 inhibitors. Considering the promising in vitro and in vivo data that have been disclosed, interest in this area of research will likely remain strong for the foreseeable future. With the first SOS1 inhibitor currently in phase I clinical trials, the outcome of these trials will likely influence future drug development of SOS1 inhibitors for treatment of RAS-driven cancers.


  • Mapping Ligand-Shape Space for Protein–Ligand Systems: Distinguishing Key-in-Lock and Hand-in-Glove Proteins

    by Joanna Zarnecka, Iva Lukac, Stephen J. Messham, Alhusein Hussin, Francesco Coppola, Steven J. Enoch, Alexander G. Dossetter, Edward J. Griffen, Andrew G. Leach

    Many of the recently developed methods to study the shape of molecules permit one conformation of one molecule to be compared to another conformation of the same or a different molecule: a relative shape. Other methods provide an absolute description of the shape of a conformation that does not rely on comparisons or overlays. Any absolute description of shape can be used to generate a self-organizing map (shape map) that places all molecular shapes relative to one another; in the studies reported here, the shape fingerprint and ultrafast shape recognition methods are employed to create such maps. In the shape maps, molecules that are near one another have similar shapes, and the maps for the 102 targets in the DUD-E set have been generated. By examining the distribution of actives in comparison with their physical-property-matched decoys, we show that the proteins of key-in-lock type (relatively rigid receptor and ligand) can be distinguished from those that are more of a hand-in-glove type (more flexible receptor and ligand). These are linked to known differences in protein flexibility and binding-site size.


  • Chemists: AI Is Here; Unite To Get the Benefits

    by Edward J. Griffen, Alexander G. Dossetter, Andrew G. Leach

    The latest developments in artificial intelligence(AI) have arrived into an existing state of creative tension between computational and medicinal chemists. At their most productive, medicinal and computational chemists have made significant progress in delivering new therapeutic agents into the clinic. However, the relationship between these communities has the prospect of being weakened by application of over-simplistic AI methods which, if they fail to deliver, will reinforce unproductive prejudices. We review what can be learnt from our history of integrating QSAR and structure-based methods into drug discovery. Now with synthesis and testing available as contract services, the environment for computational innovation has changed and we consider the impact this may have on the relationships in our disciplines. We discuss the current state of interdisciplinary communication and suggest approaches to bring the sub-disciplines together in order to improve computational medicinal chemistry and, most importantly, deliver better medicines to the clinic faster.